Search academic texts

Information × Registration Number 0213U000545, 0112U004849 , R & D reports Title To optimize the treatment of relapsed and refractory malignant lymphoma and multiple myeloma patients (multicenter study). popup.stage_title Head Kryachok Iryna, Registration Date 14-02-2013 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The object of study - 183 refractory and relapse patients with Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma. Purpose - To develop and optimize programs differentiated treatment of refractory and relapse form of Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma using modern chemotherapy regimens and stem cell transplantation based on complex clinical and hematological, imunophenotipic and molecular genetic criteria. Methods and equipments: morphological, immunohistochemical, clinical, statistical, ultrasound machine "Aloca", CT. Developed treatment protocols for patients with refractory and recurrent forms of non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma. The analysis of immediate and long-term results of complex treatment of 60 patients with refractory and relapsing forms of NHL and HL, 60 patients were treated according to the developed protocols. The treatment of patients with relapse and primary refractory forms of HL and NHL schemes II line DHAP, GVP has high efficiency. Overall response to therapy is significantly higher in patients with HL (73.3%), in patients with NHL - 50%. Primary refractory HL showed a better response to therapy compared with the group of patients with late relapse - overall response was 90 and 75%, respectively (p> 0,05). Overall response to treatment was higher in patients with late relapse LH compared with patients with early relapse LH (75 and 63%, respectively, p <0,05)). Overall and 5-year disease-free survival of patients with LH in the presence of EBV positive tumors is significantly less than in patients with HL EBV - negative (total - 62.8% and 79.1%, respectively, without relapses - 38.7% and 63 , 0%, respectively (p <0,05)). The treatment of 63 patients with multiple myeloma was done. Therapy with thalidomide has demonstrated high efficacy in patients with multiple myeloma (total efficiency was 78.8%). In analyzing the effectiveness of treatment, depending on the presence or absence of previous therapy significant differences were found (?2 = 11.527, p = 0.241). Found that the frequency of achieving complete responses in a group of primary patients and in patients previously treated no different (p> 0.05). Positive results of treatment of patients with refractory and relapse forms of non-Hodgkin lymphoma and multiple myeloma indicate its feasibility and need for further study. Product Description popup.authors Мартинчик А.В. Новосад О.І. Титоренко І.Б. Яценко Л.Д. popup.nrat_date 2020-04-02 Close